Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

Discover Avidity Biosciences' groundbreaking patent for treating facioscapulohumeral muscular dystrophy (FSHD) using a novel polynucleic acid conjugate targeting the DUX4 gene.

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

A mother and son from Georgia recently visited Kentucky for the first time. What drew them in, they say, was the ...

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing ...

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing ...

Jeni Stepanek, PhD, is known as “Mama Peace.” She spoke to WTOP from the park named after her son in the King Farm ...

Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug ...

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.